Teriflunomide
- Generic Name
- Teriflunomide
- Brand Names
- Aubagio, Teriflunomide Accord, Teriflunomide Mylan
- Drug Type
- Small Molecule
- Chemical Formula
- C12H9F3N2O2
- CAS Number
- 163451-81-8
- Unique Ingredient Identifier
- 1C058IKG3B
- Background
Teriflunomide is the active metabolite of leflunomide, and it acts as an immunomodulatory agent by inhibiting pyrimidine synthesis. It is marketed under the name Aubagio® and is indicated for the treatment of multiple sclerosis, specifically relapsing forms. The FDA label states an important warning about the risk of hepatoxicity and teratogenicity for patients using teriflunomide.
- Indication
Used in the treatment of relapsing forms of multiple sclerosis (MS).
- Associated Conditions
- Multiple Sclerosis
Phase II Study of Teriflunomide as Adjunctive Therapy to Glatiramer Acetate in Subjects With Multiple Sclerosis
- Conditions
- Multiple Sclerosis
- Interventions
- First Posted Date
- 2007-05-21
- Last Posted Date
- 2012-11-06
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 123
- Registration Number
- NCT00475865
- Locations
- 🇬🇧
Sanofi-Aventis Administrative Office, Guildford, United Kingdom
Long Term Safety and Efficacy of Teriflunomide (HMR1726) in Multiple Sclerosis With Relapses
- First Posted Date
- 2005-09-28
- Last Posted Date
- 2015-03-25
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 147
- Registration Number
- NCT00228163
- Locations
- 🇨🇦
Investigational Site Number 12, Montreal, Canada
🇨🇦Investigational Site Number 11, Montreal, Canada
🇨🇦Investigational Site Number 17, Vancouver, Canada
Study of Teriflunomide in Reducing the Frequency of Relapses and Accumulation of Disability in Patients With Multiple Sclerosis
- Conditions
- Multiple Sclerosis
- Interventions
- Drug: Placebo (for teriflunomide)
- First Posted Date
- 2005-08-25
- Last Posted Date
- 2013-01-04
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 1088
- Registration Number
- NCT00134563
- Locations
- 🇨🇦
sanofi-aventis, Canada, Laval, Canada
🇸🇪Sanofi-Aventis, Bromma, Sweden
🇩🇪Sanofi-Aventis Deutschland GmbH, Berlin, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.